Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players
Autoantibodies (Aab) are recognized as key indicators in the diagnosis, classification, and monitoring of systemic autoimmune diseases (AID). Recent studies have expanded knowledge through the discovery of new antigenic targets, advanced methods for measuring Aab levels, and understanding their poss...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Translational Autoimmunity |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909025000073 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586299375091712 |
|---|---|
| author | Aurélien Chepy Aurore Collet David Launay Sylvain Dubucquoi Vincent Sobanski |
| author_facet | Aurélien Chepy Aurore Collet David Launay Sylvain Dubucquoi Vincent Sobanski |
| author_sort | Aurélien Chepy |
| collection | DOAJ |
| description | Autoantibodies (Aab) are recognized as key indicators in the diagnosis, classification, and monitoring of systemic autoimmune diseases (AID). Recent studies have expanded knowledge through the discovery of new antigenic targets, advanced methods for measuring Aab levels, and understanding their possible pathogenic roles in AID. This narrative review uses systemic sclerosis (SSc) as an example to highlight the importance of Aab associated with HEp-2 immunofluorescence assay positivity (traditionally referred as antinuclear antibodies [ANA]), exploring recent developments in the field. Firstly, we outline the various types of ANA found in SSc and their links with specific disease features. Newly discovered antibodies shed light on SSc cases where Aab had previously gone unidentified. Secondly, we emphasize the necessity for novel quantitative techniques to track Aab levels over time by gathering data regarding the timing of Aab occurrence relative to SSc symptoms and the relationships between Aab concentrations and disease severity. Finally, we discuss the experimental findings suggesting a potential direct role of Aab in the development of SSc. The advancements surrounding Aab provide insights into new disease mechanisms and may lead to innovative diagnostic and treatment approaches. |
| format | Article |
| id | doaj-art-d1cc1adf92a747519567062878de6824 |
| institution | Kabale University |
| issn | 2589-9090 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Translational Autoimmunity |
| spelling | doaj-art-d1cc1adf92a747519567062878de68242025-01-26T05:04:43ZengElsevierJournal of Translational Autoimmunity2589-90902025-06-0110100272Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic playersAurélien Chepy0Aurore Collet1David Launay2Sylvain Dubucquoi3Vincent Sobanski4Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, FranceUniv. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France; CHU Lille, Institut d’Immunologie, Lille, FranceUniv. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, FranceUniv. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France; CHU Lille, Institut d’Immunologie, Lille, FranceUniv. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France; Institut Universitaire de France (IUF), Paris, France; Corresponding author. Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France.Autoantibodies (Aab) are recognized as key indicators in the diagnosis, classification, and monitoring of systemic autoimmune diseases (AID). Recent studies have expanded knowledge through the discovery of new antigenic targets, advanced methods for measuring Aab levels, and understanding their possible pathogenic roles in AID. This narrative review uses systemic sclerosis (SSc) as an example to highlight the importance of Aab associated with HEp-2 immunofluorescence assay positivity (traditionally referred as antinuclear antibodies [ANA]), exploring recent developments in the field. Firstly, we outline the various types of ANA found in SSc and their links with specific disease features. Newly discovered antibodies shed light on SSc cases where Aab had previously gone unidentified. Secondly, we emphasize the necessity for novel quantitative techniques to track Aab levels over time by gathering data regarding the timing of Aab occurrence relative to SSc symptoms and the relationships between Aab concentrations and disease severity. Finally, we discuss the experimental findings suggesting a potential direct role of Aab in the development of SSc. The advancements surrounding Aab provide insights into new disease mechanisms and may lead to innovative diagnostic and treatment approaches.http://www.sciencedirect.com/science/article/pii/S2589909025000073AutoantibodiesAntinuclear antibodiesSystemic sclerosisPathogenic autoantibodies |
| spellingShingle | Aurélien Chepy Aurore Collet David Launay Sylvain Dubucquoi Vincent Sobanski Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players Journal of Translational Autoimmunity Autoantibodies Antinuclear antibodies Systemic sclerosis Pathogenic autoantibodies |
| title | Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players |
| title_full | Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players |
| title_fullStr | Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players |
| title_full_unstemmed | Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players |
| title_short | Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players |
| title_sort | autoantibodies in systemic sclerosis from disease bystanders to pathogenic players |
| topic | Autoantibodies Antinuclear antibodies Systemic sclerosis Pathogenic autoantibodies |
| url | http://www.sciencedirect.com/science/article/pii/S2589909025000073 |
| work_keys_str_mv | AT aurelienchepy autoantibodiesinsystemicsclerosisfromdiseasebystanderstopathogenicplayers AT aurorecollet autoantibodiesinsystemicsclerosisfromdiseasebystanderstopathogenicplayers AT davidlaunay autoantibodiesinsystemicsclerosisfromdiseasebystanderstopathogenicplayers AT sylvaindubucquoi autoantibodiesinsystemicsclerosisfromdiseasebystanderstopathogenicplayers AT vincentsobanski autoantibodiesinsystemicsclerosisfromdiseasebystanderstopathogenicplayers |